



Salzburg
Cancer
Research
Institute

SALZBURG BREAST CANCER TALK 02. – 03.03.2018

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 2th MARCH

13:00 – 14:00 **Come together and Lunch Buffet**

14:00 **Welcome and introduction**

Richard Greil (*Salzburg*)

14:10 **Current evidence of immunotherapy in breast cancer**

Peter Schmid (*London*)

14:30 – 16:00 **Immunogenicity I: Tumor - immune cell interaction**

Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)

14:30 The role of B-cells and Tertiary Lymphoid structures (TLS)

Karen Willard-Gallo (*Brussels*)

14:50 The role of regulatory T cells, NK-cells and macrophages

Alberto Mantovani (*Milan*)

15:10 Computational genomic tools for dissecting tumor-immune cell interaction

Zlatko Trajanoski (*Innsbruck*)

15:30 Panel discussion

16:00 – 16:30 **Coffee break**

16:30 – 18:00 **Immunogenicity II: Triggers and Modulators**

Chair: Fabrice André (Paris), Richard D. Kennedy (Belfast)

16:30 Influence on immunogenicity by driver mutations

Fabrice André (*Paris*)

16:50 Influence on immunogenicity by the microbioma

Maria Rescigno (*Milan*)

17:10 Influence on immunogenicity by DNA damage response deficiency

Richard D. Kennedy (*Belfast*)

17:30 Panel discussion

18:30 **Dinner**

SATURDAY, 3th MARCH

08:30 – 10:00 **Monitoring and prediction of response to immunotherapy**

Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)

08:30 Change of immune infiltrate during treatment*

Roberto Salgado (*Brussels*)

09:00 Monitoring anti-tumor immune response in the blood*

Alexander Egle (*Salzburg*)

09:30 Prediction of response to PD-1/PD-L1 blockade*

Marleen Kok (*Amsterdam*)

10:00 Neoantigene heterogeneity*

Marco Gerlinger (*London*)

10:30 – 11:00 **Coffee break**

11:00 – 12:30 **Combination strategies with checkpoint-inhibitors**

Chair: Richard Greil (Salzburg), Simon Gampenrieder (Salzburg)

11:00 Combination with chemotherapy

Giuseppe Curigliano (*Milan*)

11:20 Combination with vaccination

Richard Greil (*Salzburg*)

11:40 Combination with radiotherapy

Udo Gaipl (*Erlangen*)

12:00 Panel discussion

12:30 **Lunch Buffet**

The Pitter Event Center
Rainerstrasse 6 – 8
5020 Salzburg

www.imaluer.com



Free WLAN-Access:
CP event_open



Prof. Dr. Richard Greil

Head of the IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Peter Schmid FRCP MD PhD

Centre Lead | Centre for Experimental Cancer
Medicine
Director, Breast Cancer, St Bartholomew
Hospital London
London, United Kingdom

Karen Willard-Gallo MD PhD

Head, Molecular Immunology Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Prof. Alberto Mantovani MD

Humanitas University
Scientific Director
Istituto Clinico Humanitas IRCCS
Milan, Italy

Prof. Dipl.-Ing. Dr. Zlatko Trajanoski

Biocenter, Division for Bioinformatics
Medical University of Innsbruck
Innsbruck, Austria

Prof. Fabrice André MD PhD

Research Director, Head of INSERM
Unit U981
Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France

Prof. Maria Rescigno PhD

Director of Dendritic cell biology and immuno-
therapy Unit
Director Immunotherapy programme,
European Institute of Oncology and
Dipartimento di Scienze della Salute, Universi-
ta' di Milano
Milan, Italy

Prof. Richard Kennedy MD PhD

Clinical Professor
Queen's University Belfast
Centre for Cancer Research and Cell Biology
Belfast, Northern Ireland, United Kingdom

Prof. Dr. Fritz Aberger

Molecular Cancer and Stem Cell Research Lab-
Department of Molecular Biology
University of Salzburg
Salzburg, Austria

Dr. Gabriel Rinnerthaler

IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Dr. Roberto Salgado

Breast Cancer Translational Research
Laboratory, Department of Pathology, GZA
Institut Jules Bordet, Brussels
Antwerp, Belgium

Priv.-Doz. Dr. Alexander Egle

IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Marleen Kok MD PhD

Research Fellow Cancer Immunotherapy
of the Dutch Cancer Society
The Netherlands Cancer Institute
Amsterdam, the Netherlands

Dr. Marco Gerlinger

Translational Oncogenomics Laboratory
Centre for Evolution and Cancer
Institute of Cancer Research
London, United Kingdom

Dr. Simon P. Gampenrieder

IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Giuseppe Curigliano MD PhD

New Drugs and Early Drug Development
for Innovative Therapies Division
European Institute of Oncology
Milan, Italy

Prof. Dr. Udo Gaipl

Head of Radiation Immunobiology
Universitätsklinikum Erlangen
Department of Radiation Oncology
Erlangen, Germany

Organization:

Richard Greil
Gabriel Rinnerthaler
Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
www.limcr.at and
Center for Clinical Cancer and Immunology Trials (SCRI-CCIT)
www.cccit.at

in cooperation with the

Cancer Cluster Salzburg | www.cancercluster-salzburg.at and AGMT gemeinnützige GmbH | www.agmt.at



Salzburg
Cancer
Research
Institute

CCCIT

Center for
Clinical Cancer
and Immunology Trials

LIMCR

Laboratory for
Immunological and
Molecular Cancer Research



CANCER
CLUSTER
SALZBURG

WWW.CANCERCLUSTER-SALZBURG.AT

AGMT

ARBEITSGEMEINSCHAFT
MEDIKAMENTÖSE
TUMORTHERAPIE